Kurve Therapeutics, Inc.
Kurve Therapeutics drug delivery technology is designed to target the most difficult part of the treatment process - getting medication through the blood-brain barrier and into the brain. Kurve Therapeutics has 18 peer-reviewed publications of clinical trials using their breakthrough technology, with further publications pending. The company has recent and ongoing collaborations with leading research centers including Harvard, Johns Hopkins, and the Karolinska Institute. Through the development of their patented Controlled Particle Dispersion technology, Kurve Therapeutics aims to reshape the landscape of cognitive aging, neurodegenerative diseases, and related disorders. Its next-generation technology has been shown to deliver up to 30x more disease-modifying medication directly to the brain than infusions in several Phase II studies. This allows for significant dose flexibility away from toxic doses for a safer, more efficacious therapy.
Company details
Find locations served, office locations
- Business Type:
- Technology
- Industry Type:
- Clinical Services
- Market Focus:
- Nationally (across the country)
About Us
Our key invention is our patented Controlled Particle Dispersion® (CPD) intranasal drug delivery technology. This next-generation technology creates a focused, turbulent flow that navigates the curved pathways of the nasal cavity, allowing access to the olfactory region. Our goal is to advance next-generation treatments for neurodegenerative diseases, including therapies with complex molecules such as monoclonal antibodies and larger peptides, by allowing medication to cross the blood-brain barrier and access the most penetrable part of the BBB at the top of the nasal cavity. Led by a team of experienced entrepreneurs with successful track records in biotech, pharmaceuticals, and device technology, our mission is to pave the way in treating complex CNS disorders, including Alzheimer’s disease, cognitive aging, Lewy body replica rolex dementia, Parkinson’s disease, and ALS. The Kurve technology is featured in 17 peer-reviewed publications in leading medical journals. Kurve technology has been used in five double-blind placebo-controlled Phase II studies and is ready for Phase III with Alzheimer’s patients.
While traditional treatment options continually prove ineffective at stopping neurodegenerative disease progression and often lead to toxicity or continued decline, Kurve is developing a new disease-modifying approach.
Our Mission and Vision
Our mission is to help as many people as we possibly can in their fight with neurodegenerative disorders. Central Nervous System (CNS) disorders are a scourge because, by their very nature, they are very difficult to treat. Our hope is that these complex, debilitating disorders may have a solution when paired with the right medication and the right technology. Our goal is to enhance the quality of life for patients and provide a solution where their past treatments have failed them. We want to bring new hope into the treatment of CNS disorders and into the lives of those suffering from them.
Our Purpose
Kurve Therapeutics was founded by a chronic sinusitis sufferer determined to cure what repeated attempts — and several surgeries — could not.
Through his extensive research and development, his first device was born. Amazed at how it helped his chronic sinusitis after years of suffering, he knew he had to share his invention with the world. He began his research with leading institutions such as Harvard and Johns Hopkins to determine how his device could be used to benefit those suffering from similar conditions, as well as a vast array of other disorders — including those with fewer treatment options.
Nose-to-brain delivery and bypassing the blood-brain barrier (BBB) have long been the elusive “holy grail” for the treatment of CNS diseases. We knew that was our target, but we also wanted to do more than that; we wanted to create a product that would effectively bypass the BBB while still allowing dosage control, with the hope of yielding higher efficacy rates than any other treatment to date.
The first clinical trial where the endpoints were met was with Kurve devices administering insulin nose-to-brain for Alzheimer’s disease. We believe our purpose is to help people, to eliminate suffering — to bring valuable change.
Core Values
If You Can Help, You Should
We believe in helping people. We refuse to sit idly if we can create solutions to ease the pain of people who are suffering.
There Is a Better Way
It’s time for a fresh take on CNS medication delivery — Kurve Therapeutics is developing a different way to treat splitweet disorders through next-generation technology that is designed to deliver medication to the brain.
Kurve Company Mission Suffering Should Not Be the Only Option
Suffering Should Not Be the Only Option
The status quo shouldn’t have to be the only option; CNS disorders are complex and hard to treat, but that doesn’t mean patients have to suffer hopelessly.
One-of-a-Kind Technology
Kurve is developing our novel Controlled Particle Dispersion (CPD)® technology. In preliminary studies, Kurve technology has shown to penetrate the BBB with a host of formulations that include: stem cells, emulsions, nanoparticles, proteins, peptides, monoclonal antibodies, polyclonal antibodies, live vaccines, inert vaccines, solutions, suspensions and combination products (systemic and nose-to-brain).